share_log

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

puma biotechnology啓動ALISCA-Breast1 II期臨床試驗,以阿利瑟替治療雌激素受體陽性、HER2陰性轉移性乳腺癌
Benzinga ·  11/20 08:58

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology 啓動 Alisertib 治療激素受體陽性、HER2 陰性的轉移性乳腺癌的 Alisca-Breast1 II 期試驗

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論